A lot of people are suddenly talking about peptides again, even if the science is… complicated. Next month, the U.S. Food and Drug Administration is set to convene an expert panel to weigh whether some licensed compounding pharmacies can manufacture certain peptides.
Peptides are short chains of amino acids—the same building blocks used to make proteins. Some exist naturally in the body, others are made synthetically. GLP-1 drugs, which have become familiar for weight management and diabetes care, are peptides too. But outside medicine, demand has shifted toward a gray market where lab-manufactured products are marketed for everything from wrinkles to inflammation to low libido.
Misryoum newsroom reported that the FDA is drawing up the discussion based on an agency filing, with a meeting scheduled for July 23 and 24. The Pharmacy Compounding Advisory Committee will consider at least seven peptides. The panel won’t make an official decision, but it will offer recommendations to the FDA.
Among the listed substances are BPC-157 for ulcerative colitis and inflammation, and TB-500 for wound healing. Misryoum editorial desk noted that other peptides on the agency’s list include KPV, which is also used for wound healing, and MOTs-C, which is used to treat obesity and osteoporosis. The lineup also contains emideltide and epitalon for sleep problems, and semax for cognitive issues. The expert discussion, then, is not just about a single compound—it’s basically about whether a category of products, often sourced from places with uneven oversight, should be manufactured through regulated compounding channels.
There’s a reason the FDA is nervous about this. Misryoum analysis indicates that many peptides sold in the DIY and influencer ecosystem have not been through thorough clinical trials. People who take them often end up buying from compounding pharmacies that make customized medications—but those customized versions aren’t individually assessed by the FDA for safety or effectiveness. Others source products from abroad, where oversight may be entirely unregulated. And yeah, it’s not hard to see why the popularity keeps rising: peptides are marketed as solutions, and the influencer-athlete loop turns “interesting” into “try it now” fast.
The political context matters too, because the FDA is under the jurisdiction of Health and Human Services Secretary Robert F. Kennedy Jr., who is vocally supportive of peptides. He has claimed to have used them himself and has pledged to end the FDA’s “war” on public health, including substances such as peptides. In a post on X on Wednesday that announced the July expert panel meetings, Kennedy said, “Today, we took long-overdue action to restore science, accountability, and the rule of law,” adding that the action “begins to restore regulated access and will immediately begin shifting demand away from the black market.” One can practically feel the room get tense around the idea of “regulated access,” especially when the gray market has been driving demand.
A small real-world detail sticks with me: the way the hum of an elevator can carry over a lobby conversation—like people are talking past each other. Here, that mismatch is between people chasing quick answers and regulators trying to slow the pace. The panel’s recommendations may help, but they won’t magically prove which peptides truly work, or for whom. And if any of this ends up changing how pharmacies manufacture peptides, it will also raise the question of what “safe” and “effective” should mean for products that have already circulated far beyond clinical pathways.
Artemis II astronauts return to Houston after moonshot